Skip to main content

MS news

Our news web pages include ground-breaking multiple sclerosis news and research from around the world. 

These news stories are taken from external sources and as such, MS-UK does not verify, endorse or accept responsibility for their content.

Some of these pages have been written for medical professionals and this can be reflected in the complexity of language and content.

Supporting you

We’re here to support you, whether you are awaiting a diagnosis of multiple sclerosis or have been living with the condition for years. 

Find out more about the MS-UK Helpline

Find out more about our Choices booklets

Find out more about New Pathways magazine

 


A new tool to help multiple sclerosis (MS) patients choose the best treatment for them. There are currently 18 approved disease-modifying therapies available on the NHS in the UK, and a group of...
People with multiple sclerosis (MS) who experience restless leg syndrome are more likely to have greater disability and MRI lesions than those who do not, a new study has found. The study’s...
Mindfulness can reduce depression in people with multiple sclerosis (MS), a new study has found. The research, which took place in an outpatient clinic in Germany, found that reducing depression also...
The majority of people with multiple sclerosis (MS) who catch Covid-19 go on to experience worsening of current symptoms, or new symptoms, a new survey has found. The UK MS Register Covid-19 study...
A new study has found that high blood levels of the proteins neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) can indicate an increased risk of worsening disability in...
Over a third of people living with multiple sclerosis (MS) have hidden their condition from others, a new survey has found. Out of the 800 people with MS asked, one in 10 people admitted they had...
The National Institute for Health and Care Excellence (NICE) has recommended Kesimpta (ofatumumab), which is a new treatment for people with multiple sclerosis (MS), to be prescribed on the NHS in...
Multiple sclerosis (MS) prevalence rises with countries’ prosperity, according to a new study, and occurs more in developed countries. Researchers used data from 195 countries that was collected in...
Tysabri (natalizumab) significantly reduces disease activity and the number of relapses in people with paediatric-onset multiple sclerosis (POMS), new real-world study from Portugal has found....
A new nine-year study has found that abnormalities seen on MRI scans in children with multiple sclerosis (MS) at the onset of the condition, and within the first two years, might predict how their...

Pages